List of Astepro drug patents
Astepro is owned by Mylan Speciality Lp.
Astepro contains Azelastine Hydrochloride.
Astepro has a total of 3 drug patents out of which 0 drug patents have expired.
Astepro was authorised for market use on 15 October, 2008.
Astepro is available in spray, metered;nasal dosage forms.
Astepro can be used as treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis.
The generics of Astepro are possible to be released after 04 June, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8518919 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Nov, 2025
(2 years from now) | |
| US9919050 | MYLAN SPECIALITY LP | Compositions comprising azelastine |
Nov, 2025
(2 years from now) | |
| US8071073 | MYLAN SPECIALITY LP | Compositions comprising azelastine and methods of use thereof |
Jun, 2028
(5 years from now) | |
Drugs and Companies using AZELASTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2008
Treatment: Treatment of allergic rhinitis, including seasonal and perennial allergic rhinitis
Dosage: SPRAY, METERED;NASAL
ASTEPRO family patents
9
United States
4
European Union
3
Spain
3
Denmark
3
Poland
3
Korea, Republic of
3
Portugal
3
Australia
3
Lithuania
3
Slovenia
2
Japan
2
Israel
2
Mexico
2
Hungary
1
Hong Kong
1
Turkey
1
RS
1
China
1
Brazil
1
Canada
1
New Zealand
1
Croatia
1
Cyprus
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic